Male Contraception Clinical Trial
Official title:
Double-blind, Placebo Controlled, First in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of YCT-529
A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.
This is a Phase 1a, double-blind, placebo controlled, first in human study to evaluate the safety, tolerability, PK, and PD of YCT-529 in 2 cohorts of 8 subjects. Cohorts 1 and 2 will be dosed in the fasted state in Periods 1 and 2. Each cohort will receive two doses of study drug separated by a washout period. One cohort will then return for a third dose of study drug under fed conditions in Period 3 to study the effect of food on YCT-529. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03452111 -
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
|
Phase 2 | |
| Active, not recruiting |
NCT03298373 -
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
|
Phase 1 | |
| Completed |
NCT01382069 -
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
|
Phase 1 | |
| Completed |
NCT02994602 -
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
|
Phase 1 | |
| Recruiting |
NCT02927210 -
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
|
Phase 1 | |
| Active, not recruiting |
NCT02754687 -
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
|
Phase 1 | |
| Recruiting |
NCT03455075 -
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
|
Phase 2 |